FOXP3 Blocking Peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q99JB6 |
---|---|
Other Accession | NP_473380 |
Gene ID | 20371 |
Calculated MW | 47346 Da |
Gene ID | 20371 |
---|---|
Application & Usage | The peptide is used for blocking the antibody activity of FOXP3. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C. |
Other Names | Forkhead box protein P3, Scurfin, Foxp3 |
Target/Specificity | FOXP3 |
Formulation | 50 µg (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | FOXP3 Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Foxp3 |
---|---|
Function | Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg) (PubMed:22813742). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases. The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2 (PubMed:15790681). Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7 (By similarity). Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1 (PubMed:17377532). Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development (PubMed:18368049). Inhibits the transcriptional activator activity of RORA (By similarity). Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (PubMed:19696312). |
Cellular Location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00089, ECO:0000269|PubMed:17377532, ECO:0000269|PubMed:18368049}. Cytoplasm {ECO:0000250|UniProtKB:Q9BZS1}. Note=Predominantly expressed in the cytoplasm in activated conventional T-cells whereas predominantly expressed in the nucleus in regulatory T-cells (Treg) (By similarity) The 41 kDa form derived by proteolytic processing is found exclusively in the chromatin fraction of activated Treg cells {ECO:0000250|UniProtKB:Q9BZS1, ECO:0000269|PubMed:19117830} |
Tissue Location | High level of expression in thymus and spleen. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.